YPrime’s Karl McEvoy Appointed as eCOA Consortium Industry Co-Director for 2025
January 14, 2025 08:00 ET
|
Y-Prime, LLC
YPrime's Dr. Karl McEvoy, VP eCOA & Patient Technologies, has been appointed Industry Co-Director of the Critical Path Institute (C-Path) eCOA Consortium
Franklin Access (Formerly Franklin Wireless) Successfully Defends Shareholder Litigation
December 24, 2024 13:00 ET
|
Franklin Wireless Corporation
SAN DIEGO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Franklin Access is pleased to announce a significant legal victory in its shareholder litigation, “In re Franklin Wireless Corp. Derivative Litigation”,...
BIOA BREAKING NEWS: BFA Law Announces an Investigation into BioAge Labs, Inc. after Stock Plummets 76% -- Contact the Firm if You Lost Money (NASDAQ:BIOA)
December 10, 2024 12:49 ET
|
Bleichmar Fonti & Auld
BioAge Labs, Inc. investors that lost money are encouraged to contact BFA Law about its securities fraud investigation into the Company.
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
November 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Legendary Attorney Glenn Zeitz Launches Podcast: Philly Trial Lawyer Stories
October 24, 2024 10:00 ET
|
Glenn Zeitz
PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Philly Trial Lawyer Stories, a new podcast from legendary attorney Glenn Zeitz, is set to launch on October 23rd offering listeners an exclusive,...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 30, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024 07:00 ET
|
OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
May 22, 2024 10:23 ET
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.